New Mechanism Developed to Enhance Anti-Cancer Drug Efficacy for Breast Cancer Treatment

Researchers at the Council of Scientific and Industrial Research - Central Drug Research Institute (CSIR-CDRI) have recently introduced a new method to boost the effectiveness of anti-cancer drugs in treating breast cancer. The innovative approach not only enhances the drug's potency against cancerous cells but also prevents it from affecting healthy cells.

The lead scientist, Manish Chourasia, explained that they have designed a unique double-shell magnetic nanoparticle system that specifically targets cancer-causing cells while sparing normal cells. By attaching these nanoparticles to common chemotherapy drugs like doxorubicin, the team has observed increased drug efficiency and reduced toxicity levels.

Chourasia highlighted that women with iron deficiency are particularly vulnerable to developing breast cancer. Iron deficiency also raises the risk of cancer recurrence or secondary cancer. The double-shelled magnetic nanoparticle system can aid in iron supplementation while containing retinoic acid, an immune-modulating substance that stimulates the body's defense against cancer.

This groundbreaking mechanism offers new possibilities for breast cancer treatment by combining targeted therapy with immune modulation. The team's findings represent a significant advancement in the field of oncology and hold promise for improving patient outcomes and quality of life.